Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of biolimus-eluting stent with biodegradable polymer: insights from EINSTEIN (Evaluation of Next-generation drug-eluting STEnt IN patients with coronary artery disease) Registry.
Souza CF, El Mouallem AM, de Brito Júnior FS, Abizaid AA, Almeida BO, Almeida AG, Nascimento TC, Perin MA, Caixeta A. Souza CF, et al. Among authors: almeida ag, almeida bo. Einstein (Sao Paulo). 2013 Jul-Sep;11(3):350-6. doi: 10.1590/s1679-45082013000300015. Einstein (Sao Paulo). 2013. PMID: 24136763 Free PMC article.
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Feres F, Costa RA, Abizaid A, Leon MB, Marin-Neto JA, Botelho RV, King SB 3rd, Negoita M, Liu M, de Paula JE, Mangione JA, Meireles GX, Castello HJ Jr, Nicolela EL Jr, Perin MA, Devito FS, Labrunie A, Salvadori D Jr, Gusmão M, Staico R, Costa JR Jr, de Castro JP, Abizaid AS, Bhatt DL; OPTIMIZE Trial Investigators. Feres F, et al. JAMA. 2013 Dec 18;310(23):2510-22. doi: 10.1001/jama.2013.282183. JAMA. 2013. PMID: 24177257 Clinical Trial.
Improvement of renal function after transcatheter aortic valve replacement in patients with chronic kidney disease.
Lemes da Silva MV, Nunes Filho ACB, Rosa VEE, Caixeta A, Lemos Neto PA, Ribeiro HB, Almeida BO, Mariani J Jr, Campos CM, Abizaid AAC, Mangione JA, Sampaio RO, Caramori P, Sarmento-Leite R, Tarasoutchi F, Franken M, de Brito FS Jr. Lemes da Silva MV, et al. Among authors: almeida bo. PLoS One. 2021 May 13;16(5):e0251066. doi: 10.1371/journal.pone.0251066. eCollection 2021. PLoS One. 2021. PMID: 33984005 Free PMC article.
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.
Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW; APPROACH Study Group. Gerstein HC, et al. Circulation. 2010 Mar 16;121(10):1176-87. doi: 10.1161/CIRCULATIONAHA.109.881003. Epub 2010 Mar 1. Circulation. 2010. PMID: 20194881 Clinical Trial.
41 results